Update MRONJ and perspectives of its treatment - 07/09/17
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
| páginas | 4 |
| Iconografías | 4 |
| Vídeos | 0 |
| Otros | 0 |
Abstract |
Antiresorptive agents are widely used in catabolic bone diseases. Not only bisphosphonates but also new drugs like Denosumab may induce osteonecrosis of the jaw as a side effect. The present review describes the current effect mechanisms of commonly used antiresorptives, pathogenetic theories for the development of antiresorptive-related osteonecrosis of the jaw (ARONJ), and potential risk factors. Furthermore, diagnostic modalities and treatment options as well as new and innovative strategies are discussed. The major key factor to avoid the occurrence of ARONJ still remains the implementation of throughout preventive measures.
El texto completo de este artículo está disponible en PDF.Keywords : Bisphosphonates, Osteonecrosis of the jaw, Denosumab, ARONJ
Esquema
| ☆ | Article reported from the 53rd SFSCMFCO Congress (Marseille, October 4–7, 2017) and published under the responsibility of the Scientific Committee of the congress. |
Vol 118 - N° 4
P. 232-235 - septembre 2017 Regresar al número
Artículo precedente
- Platelet-rich plasma-enriched autologous fat graft in regenerative and aesthetic facial surgery: Technical note
- F. Picard, B. Hersant, S. La Padula, J.-P. Meningaud
- Use of platelet-rich plasma (PRP) in microsurgery
- B. Hersant, S. La Padula, M. SidAhmed-Mezi, A.M. Rodriguez, J.P. Meningaud
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?